Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

by Team Lumida
April 2, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
a man holding a ball in his right hand

Photo by julien Tromeur on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • 94% of physicians have already adopted AI tools or are interested in doing so, with more than half now using AI in their practice — up from 47% in early 2025 to 63% by late 2025 and early 2026, per a Doximity survey of over 3,000 doctors
  • More than 70% of physicians cited accuracy and reliability as a top barrier to broader AI adoption, and nearly half pointed to legal and regulatory uncertainty
  • Three-quarters of physicians who had already adopted AI reported reduced administrative burden and better job satisfaction; nearly half said AI improved their capacity to take on new patients
  • Only 8% of physicians said their organization’s AI decision-making process is clear and well-understood — while about half said it is “still evolving” — highlighting a significant governance gap

What Happened?

A new survey by Doximity, the medical professional network and technology company, finds that AI adoption among physicians is accelerating rapidly — but concerns about accuracy and unclear organizational governance are slowing full integration. Of more than 3,000 physicians surveyed across two periods, 94% said they had already adopted AI tools or are interested in doing so, with just 5% saying they weren’t interested. Adoption has surged: 47% reported using AI during the first survey period in early 2025; by the second period from November through January, that figure had risen to 63%. The most common use cases were literature search and AI-powered scribing tools that record patient conversations and draft clinical documentation. Despite the rapid adoption, more than 70% cited accuracy and reliability as a top barrier, and nearly half flagged legal and regulatory uncertainty as a concern.

Why It Matters?

The Doximity survey captures a pivotal inflection point in healthcare AI: the technology has crossed from “early adopter” territory to mainstream clinical interest in under three years, but the infrastructure — governance, regulation, and trust — hasn’t kept pace. The gap is most visible in organizational readiness: only 8% of physicians said their organization’s AI policies and guidelines are clear, while about half said the process is “still evolving.” That ambiguity creates liability exposure for health systems and confusion for individual clinicians trying to deploy AI responsibly. For healthcare investors, the survey underscores both the size of the opportunity and the friction that remains. The AI tools generating the most physician enthusiasm — scribing, literature search, administrative automation — are also among the lower-risk applications, suggesting adoption will continue to build from the bottom up before moving into higher-stakes clinical decision support.

What’s Next?

The governance gap is the most actionable finding for health systems: with 92% of physicians either using or interested in AI, the question is no longer whether to deploy these tools but how to deploy them safely and with clear institutional policies. Organizations that move quickly to establish clear guidelines, training, and accountability frameworks will be better positioned to capture the productivity and retention benefits AI can deliver — and to avoid the legal and regulatory exposure that currently concerns nearly half of physicians. For AI vendors, the survey signals strong underlying demand but also the need to invest in accuracy validation and explainability, given that reliability concerns are the top barrier. Regulatory clarity from the FDA and CMS on AI-powered clinical tools will be a critical catalyst for the next phase of adoption.

Source: Healthcare Dive

Previous Post

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

Next Post

Trump Threatens to Escalate Iran War — But Says End Is ‘Very Close’

Recommended For You

Patients Are Using AI to Interpret Their Medical Test Results Before Seeing Doctors — And Doctors Are Struggling to Untangle the Errors

by Team Lumida
2 hours ago
doctor holding red stethoscope

Roughly a third of American adults now consult AI for health advice, and the majority view test results online before speaking with a doctor — a trend accelerated...

Read more

Novo Nordisk’s $10 Billion Cardiovascular Bet Fails — Ziltivekimab Misses Heart Attack and Stroke Endpoint, Stock Drops 10.5%

by Team Lumida
7 days ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk's experimental drug ziltivekimab — a monthly IL-6 inhibitor injection targeting cardiovascular disease, chronic kidney disease, and inflammation in a market Jefferies estimates at $10B+ annually —...

Read more

Trump Administration to End $3.6 Billion Medicare Drug Premium Subsidy — Seniors Face Higher Part D Costs in 2027

by Team Lumida
1 week ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The Trump administration will not renew the Part D Low Income Premium Subsidy program after 2026, eliminating $3.6 billion in annual payments to insurers that have been holding...

Read more

80% of People Are Deficient in Essential Vitamins — Here Are the 10 You Actually Need and Where to Get Them

by Team Lumida
2 weeks ago
oranges, peas, and limes on a wooden table

Most people are not getting enough of the 13 essential vitamins their bodies require — here is a practical guide to the most critical nutrients, what they do,...

Read more

Whoop Enters Clinical Care With Joint Replacement Recovery Pilot — Can Wearable Biometrics Reduce Opioids and Speed Recovery?

by Team Lumida
3 weeks ago
a close up of a human skull on a black background

Whoop and surgical software company Kinomatic have launched a 12-week pilot program called Restore across three California orthopedic clinics to test whether continuous biometric monitoring — heart rate...

Read more

$399 Signal Ring Claims to Replace the Blood Pressure Cuff — No Calibration, No Subscription, Clinical Trial at Stanford

by Team Lumida
3 weeks ago
Fingers hold a black smart ring with circuits visible.

Vital Signals, a three-year-old startup, has launched a $399 Signal Ring that claims to track blood pressure as accurately as a traditional arm cuff — without requiring any...

Read more

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
3 weeks ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more

Information Blocking in Healthcare Is Down — But a Stubborn Minority of IT Vendors Keep Doing It Routinely

by Team Lumida
4 weeks ago
doctor holding red stethoscope

The share of health information exchanges reporting instances of information blocking fell from over 90% in 2019 to 71% in 2025, according to new ONC data — but...

Read more

Novo Nordisk Squeezes Suppliers for Discounts as Eli Lilly Eats Its Lunch in the Obesity Drug Market

by Team Lumida
1 month ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk has written to suppliers seeking price discounts to protect its cost base as it fights to claw back market share lost to Eli Lilly in the...

Read more

Medicare Launches $50/Month Weight-Loss Drug Coverage Today — With Caveats

by Team Lumida
1 month ago
GLP-1 Drugs Are Triggering a Returns Crisis for America’s Apparel Retailers

Medicare's "Bridge" program kicks off July 1, offering Wegovy and Zepbound to 12.5–20 million eligible seniors at a $50 monthly copay — down from up to $450 cash...

Read more
Next Post
House Rebuke of Canada Tariffs Exposes Political Risk Around Trump’s Trade Agenda

Trump Threatens to Escalate Iran War — But Says End Is 'Very Close'

Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

Supreme Court Signals It Will Strike Down Trump's Birthright Citizenship Order

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Microsoft’s Blue Screen of Death: What You Need to Know

Microsoft’s Cloud and AI Demand Drive Blowout Quarter, Shares Surge

July 31, 2025
OpenAI Hack: Why AI Companies Are Prime Targets for Cyberattacks

OpenAI Strikes Truce on Child AI Safety, Backing California Ballot Compromise

January 10, 2026
ASML Q2 2024 Earnings Summary

ASML Pitches for India Business as Modi Eyes Local Chip Making

September 2, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018